R21TW012623

ASKDOKI: EVALUATION OF A MOBILE HEALTH INTERVENTION TO IMPROVE SEXUAL AND REPRODUCTIVE HEALTH OUTCOMES AMONG KENYAN ADOLESCENTS LIVING INURBAN INFORMAL SETTLEMENTS - ABSTRACT/PROJECT SUMMARY DESPITE RECENT IMPROVEMENTS IN ADOLESCENT SEXUAL AND REPRODUCTIVE HEALTH (ASRH) OUTCOMES IN KENYA, RATES OF UNSAFE SEX, UNPLANNED PREGNANCY, ABORTION, AND SEXUALLY TRANSMITTED INFECTIONS REMAIN HIGH. WHILE SCHOOLBASED COMPREHENSIVE SEXUALITY EDUCATION (CSE) IMPROVES ASRH OUTCOMES, THE KENYAN GOVERNMENT TENDS TO SUPPORT LESS THOROUGH PROGRAMS, AND TEACHERS FACE CHALLENGES (E.G., LACK OF TIME, TRAINING, RESOURCES) THAT HINDER SEXUALITY EDUCATION INSTRUCTION. ADOLESCENTS WHO DO NOT RECEIVE ADEQUATE CSE INSTRUCTION LACK THE INFORMATION NEEDED TO MAKE INFORMED SEXUAL AND REPRODUCTIVE HEALTH DECISIONS. THUS, THERE IS PRESSING NEED TO IDENTIFY INNOVATIVE INTERVENTIONS TO PROVIDE CSE OUTSIDE THE FORMAL EDUCATIONAL SYSTEM. MOBILE HEALTH (MHEALTH) TECHNOLOGY MAY PROVIDE A COST-EFFECTIVE SOLUTION. AMREF HEALTH AFRICA–KENYA DEVELOPED/TESTED AN ARTIFICIALLY INTELLIGENT MHEALTH WHATSAPP CHAT BOT, ASKDOKI, TO DELIVER CSE. PRELIMINARY DATA SUGGEST IMPROVED EFFECTIVENESS AND OUTREACH MIGHT BE OBTAINED, ESPECIALLY AMONG ADOLESCENTS WHO LACK PHONES, BY PAIRING ASKDOKI WITH “TECH SAVVY” YOUTH PEER LEADERS OR “DIGITAL CHAMPIONS” (DCS). IN COLLABORATION WITH AMREF, WE WILL IMPLEMENT ASKDOKI AMONG ADOLESCENTS VIA DC OUTREACH AND FACILITATION TO ADDRESS OUR SPECIFIC AIMS: R21 AIM 1A) EXAMINE THE EFFECTIVENESS OF ASKDOKI-DELIVERED CSE IN IMPROVING KEY DETERMINANTS OF ASRH BEHAVIORS/ OUTCOMES VIA A QUASI-EXPERIMENTAL, TWO-GROUP (INTERVENTION VS. CONTROL CLUSTERS), NON-EQUIVALENT, PRE/POST SURVEY DESIGN WITH ADOLESCENTS AGED 15-19. PRIMARY OUTCOMES FOR COMPARISON WILL BE INCREASES IN PERCEIVED CONTROL (E.G., CONDOM-USE SELF-EFFICACY), POSITIVE ATTITUDES (E.G., CONDOM USE), SUBJECTIVE NORMS (E.G., PEER SUPPORT OF CONDOM USE), KNOWLEDGE (E.G., PREGNANCY, STIS), AND INTENTIONS (E.G., TO USE CONDOMS). R21 AIM 1B) CONDUCT A PROCESS EVALUATION OF THE DC STRATEGY TO PROMOTE/FACILITATE ASKDOKI ACCESS. WE WILL COLLECT DATA FROM MULTIPLE SOURCES TO ASSESS ADOLESCENT REACH, ACCEPTABILITY, AND UPTAKE OF THE DC STRATEGY. WE WILL ALSO CONDUCT TWO SETS OF FOCUS GROUPS: WITH AIM 1A ADOLESCENTS TO EXPLORE DC PERCEPTIONS AND EXPERIENCES AND TO IDENTIFY IMPROVEMENT AREAS; AND WITH DCS TO EXPLORE BARRIERS AND FACILITATORS. R21 AIM 2) CONDUCT COST EFFECTIVENESS ANALYSES FOR THE ASKDOKI AND DC STRATEGY. WE WILL TRACK START-UP, OPERATIONAL, AND INCREMENTAL PER-USE COSTS AND COMPUTE COST PER ADOLESCENT SERVED AND COST PER ADOLESCENT WHO MAKES PROGRESS ON ONE AND ON AT LEAST THREE OUTCOME MEASURES. R33 AIM 3) EVALUATE A SCALED DEPLOYMENT OF ASKDOKI USING RE-AIM FRAMEWORK. WE WILL EXAMINE REACH (ADOLESCENTS ACCESSING ASKDOKI), EFFECTIVENESS (AIM 1 OUTCOMES, CONDOM USE, PREGNANCY REDUCTION, WILLINGNESS TO TEST/TREAT STIS, USE OF SRH SERVICES); ADOPTION (REPRESENTATIVENESS OF ASKDOKI USERS, CHARACTERISTICS OF CURRICULUM COMPLETERS); IMPLEMENTATION (INTERVIEWS WITH ADOLESCENTS TO EXPLORE BARRIERS, FACILITATORS, SCALED DEPLOYMENT COST); AND MAINTENANCE (SUSTAINED EFFECTIVENESS OF PRIMARY/SECONDARY OUTCOMES). FINDINGS MAY INFORM SCALABLE INTERVENTIONS THAT PROVIDE U.S. ADOLESCENTS WITH HEALTH INFORMATION THAT ULTIMATELY HELPS TO IMPROVE YOUTH OUTCOMES.

Pacific Institute For Research & Evaluation

THE JOHN E. FOGARTY INTERNATIONAL CENTER (FIC) SUPPORTS RESEARCH AND RESEARCH TRAINING TO REDUCE DISPARITIES IN GLOBAL HEALTH AND TO FOSTER PARTNERSHIPS BETWEEN U.S. SCIENTISTS AND THEIR COUNTERPARTS ABROAD. FIC SUPPORTS BASIC BIOLOGICAL, BEHAVIORAL, AND SOCIAL SCIENCE RESEARCH, AS WELL AS RELATED RESEARCH TRAINING AND CAREER DEVELOPMENT. THE RESEARCH PORTFOLIO IS DIVIDED INTO SEVERAL PROGRAMS THAT SUPPORT A WIDE VARIETY OF FUNDING MECHANISMS TO MEET PROGRAMMATIC OBJECTIVES.

93.989 - International Research and Research Training

Fogarty International Center (FIC) [HHS - NIH]

Chapel Hill, North Carolina 275147038 United States

Single Zip Code

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) (PAR-23-318)

Amendment Since initial award the total obligations have increased 71% from $99,740 to $170,799.